ORIGINAL RESEARCH
Accepted on 14 Apr 2025
A conceptual exploration on the synergistic anti-tumor effects of high-order combination of OHSV2-DSTE FAP5/CD3 , CAR-T cells, and immunotoxins in hepatocellular carcinoma
doi 10.3389/fimmu.2025.1509087
- Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- Research Topics
- Advancements in Antibody-Based Immunotherapy and Cancer Vaccines for Hepatocellular Carcinoma
Advancements in Antibody-Based Immunotherapy and Cancer Vaccines for Hepatocellular Carcinoma
2,767
Total downloads
8,587
Total views and downloads
Submit your idea
Select the journal/section where you want your idea to be submitted:
Articles
ORIGINAL RESEARCH
Published on 10 Dec 2024
Prognostic significance of combined PD-L1 expression in malignant and infiltrating cells in hepatocellular carcinoma treated with atezolizumab and bevacizumab
doi 10.3389/fimmu.2024.1506355
- 849 views
ORIGINAL RESEARCH
Published on 23 Oct 2024
Comparing PD-L1 with PD-1 antibodies combined with lenvatinib and hepatic arterial infusion chemotherapy for unresectable hepatocellular carcinoma
doi 10.3389/fimmu.2024.1491857
- 1,426 views
- 1 citation
SYSTEMATIC REVIEW
Published on 02 Aug 2024
Immune-targeted therapy with transarterial chemo(embolization) for unresectable HCC: a systematic review and meta-analysis
doi 10.3389/fimmu.2024.1421520
- 1,605 views
- 2 citations
ORIGINAL RESEARCH
Published on 26 Jul 2024
TACE plus lenvatinib and tislelizumab for intermediate-stage hepatocellular carcinoma beyond up-to-11 criteria: a multicenter cohort study
doi 10.3389/fimmu.2024.1430571
- 1,507 views
- 2 citations
Published in
Frontiers in Immunology
Cancer Immunity and Immunotherapy
Participating Journals
Frontiers in Oncology
- 3.5 impact factor
- 6.2 citescore
Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.
Submit your idea
Select the journal/section where you want your idea to be submitted: